By Heather Landi
The largest healthcare conference to put on an on-site event since the start of the COVID-19 pandemic will require attendees and exhibitors to show proof of full vaccination.
read more
By Arlene Weintraub
Many biopharma companies are betting the novel coronavirus is here to stay—and they’re continuing to develop vaccines and drug treatments to keep it under control. They include CureVac, which said the next-gen version of its mRNA COVID vaccine was effective in a rodent study, and Memo Therapeutics, which described the antibody drug candidate it's developing.
read more
By Robert King
New data released by CMS show how far mental health services declined among beneficiaries on Medicaid and CHIP from March through October 2020 due to the pandemic.
read more
By Noah Higgins-Dunn
AstraZeneca’s Farxiga may not have hit its marks in a COVID-19 trial, but it did well enough to keep trying, the study’s lead author said. On top of that, its performance on the safety side may help dispel doctors' fears that SGLT2 drugs could cause serious side effects in COVID-19 patients.
read more
By Healthcare Staff
Follow along with the latest COVID-19 news straight from the Fierce Healthcare team.
read more
By Noah Higgins-Dunn,Kevin Dunleavy,Fraiser Kansteiner
Sanofi and GSK reported their COVID-19 vaccine performed well in a phase 2 study, and now the pair plan on initiating a larger phase 3 trial with the aim of a late 2021 approval. UNICEF's chief called on G7 countries to make an emergency donation of doses to COVAX, which is facing supply shortages. And more headlines.
read more
By Conor Hale
The AI was more accurate in predicting severe cases than a panel of experts trained in echocardiograms, while the study also showed that the use of AI led to less variability between scans and readers.
read more
By Kevin Dunleavy
A study of T cell responses shows that mRNA vaccines produced by Moderna and Pfizer-BioNTech are as effective against the U.K. and South African variants of COVID-19 as they are against the original strain, among other findings.
read more
By Conor Hale
PerkinElmer aims to spend some of the windfall its reaped over the past year from COVID-19 testing on a new acquisition, and similarly tapping yet another smaller European test maker to bolster its core business.
read more
.jpg)
